Omitting criteria for enrichment of a high‐risk HF population such as BNP/NT‐proBNP levels or events due to worsening of HF within the last 12 month before recruitment may reduce the number of relevant endpoint events and therefore the power of the trial. The gene discussed is NPPB; the disease is hydrops fetalis.